

1 **Simplified Co-extraction of total Nucleic Acids from Respiratory Samples for detection of**
2 ***Mycobacterium tuberculosis* and SARS-CoV-2 optimized for compatibility across Diagnostic**
3 **Platforms**

4
5 **Nisha H. Modi¹, Owen R. S. Dunkley², Alexandra G. Bell², Emily Hennig¹, Aanchal Wats¹, Yujia**
6 **Huang², Naranjargal Daivaa¹, Cameron Myhrvold^{2,3,4,5*}, Yingda L. Xie^{1*}, Padmapriya Banada^{1*,^}**

7 ¹Department of Medicine, International Center for Public Health, Rutgers University, Newark, NJ, 07103,

8 ²Department of Molecular Biology, Princeton University, Princeton, NJ, 08544

9 ³Department of Chemical and Biological Engineering, Princeton University, Princeton, NJ 08544

10 ⁴Omenn-Darling Bioengineering Institute, Princeton University, Princeton, NJ 08544

11 ⁵Department of Chemistry, Princeton University, Princeton, NJ 08544

12

13 *Equal contribution

14 ^Corresponding author; priya.banada@rutgers.edu

15

16

1 **ABSTRACT**

2
3 Tuberculosis (TB) and COVID-19 are leading infectious diseases with high mortality, caused by
4 *Mycobacterium tuberculosis* (*Mtb*) and SARS-CoV-2 (*SC2*), respectively. Co-infection is common but is
5 often undiagnosed as it is challenging to process both pathogens from a single sample. In this study, we
6 present a simple and efficient method for co-extracting nucleic acids (NA) from these two distinct
7 respiratory pathogens for downstream diagnostic testing. We evaluated three different nucleic acid
8 amplification (NAA)-based platforms, LightCycler480 (LC480) qPCR, Qiauity digital PCR (dPCR), and
9 Cytation3 for CRISPR-Cas13a-based SHINE-TB/SC2 detection assays. Chelex-100 chelating resin-based
10 boiling preparation method was optimized for *Mtb* NA extraction from saliva and sputum. Saliva showed
11 compatibility with all three platforms, with sensitivity as low as 100 CFU/ml (or 2 genomic copies/μl).
12 This method worked well for sputum using dPCR at 100% (21/21) positivity, though the CRISPR-based
13 SHINE-TB assay showed more variability and sensitivity to sputum inhibitor carry-over, resulting in an
14 81% positive rate (17/21). Diluting sputum with TE buffer (1:1) improved the detection (2/4). Extraction
15 efficiency of our method was 48%, 62.2%, 86.4% and 99.3% for concentrations 10^5 , 10^4 , 10^3 and 10^2
16 CFU/ml, respectively. The dynamic range for *Mtb* spiked in pooled sputum showed 100% detection
17 (N=8) at $\geq 10^3$ CFU/ml with all three methods. Dual-pathogen co-extraction and detection of *SC2* (10^5
18 PFU/ml) and *Mtb* (10^5 CFU/ml) in salivary sputum was successful using CRISPR-Cas13a assays. We
19 have developed a rapid and efficient co-extraction method for multi-pathogen testing across diagnostic
20 platforms and believe this is the first protocol optimized to co-extract *Mtb* and SARS-CoV-2 from a single
21 sample.

22

23

1 INTRODUCTION

2
3 Tuberculosis (TB) and COVID-19 are two of the deadliest infectious diseases worldwide, affecting
4 millions of people each year. TB is caused by *Mycobacterium tuberculosis* (*Mtb*), an acid-fast bacterium
5 while COVID-19 is caused by a coronavirus *SARS-CoV-2* (*SC2*) (1). COVID-19 has led to >7 million
6 deaths worldwide, and continues to be a major health challenge as new variants emerge (2). In 2023, an
7 estimated 10.8 million people developed TB, with 8.2 million diagnosed and 1.25 million deaths reported
8 (3, 4). TB and COVID-19 remain significant public health crises, especially in endemic countries where
9 medical resources, treatment, and community interventions are scarce (5-7). The global efforts to
10 eliminate TB were largely set back due to COVID-19 pandemic, which led to a rise in undiagnosed TB
11 cases due to diversion of public health intervention programs away from TB towards COVID-19 (3, 8-
12 11). This highlights the need for scalable multi-pathogen surveillance approaches implementable in
13 community clinics for effective management and control of epidemics (12, 13) currently and in future.

14 COVID-19 and TB are respiratory diseases that primarily affect the lungs and can be diagnosed
15 using respiratory samples (1, 14). Sputum is commonly used for diagnosing pulmonary TB while
16 nasopharyngeal, nasal and saliva are often preferred for *SC2* (15-17). It is possible that a single sample
17 type could be used for detection of both pathogens (12). Sputum can be difficult to collect from TB
18 patients especially in vulnerable populations such as HIV positive, children, and the elderly. Often,
19 multiple sample collections or invasive procedures are required to obtain a high-quality sputum sample,
20 highlighting the need for alternative sample types for diagnostics. Various sample types including saliva,
21 have been explored in recent years with promising results for pulmonary TB diagnosis (18, 19). Saliva
22 has offered comparable sensitivity to sputum in lab developed tests (18). Similarly, sputum samples have
23 showed equal or better sensitivity than oropharyngeal samples for COVID-19 testing (15), suggesting that
24 either saliva or sputum could serve as single collection type for both TB and COVID-19 diagnosis.

25 Nucleic acid-based (NA) molecular diagnostic tests have significantly improved TB and COVID-
26 19 diagnosis in terms of time, sensitivity, specificity and overall cost-effectiveness compared to traditional

1 methods (14, 20-22). A variety of NA-based tests, including those developed by our team, have proven
2 highly efficient for detecting TB and COVID-19 (23-30). However, there remains a gap in achieving
3 optimal diagnostic yield, where the test accurately identifies all individuals with the infection (31). This
4 gap could be due to the sample type requirements for certain tests or inefficient nucleic acid extraction
5 limiting the test's performance (32-35). To facilitate timely diagnosis in resource-limited settings, nucleic
6 acid extraction from sample types containing mixed pathogens must be rapid, efficient, simple, and cost-
7 effective.

8 In this study, we demonstrate the optimization and development of a simple total nucleic acid
9 (DNA and RNA) extraction method by adapting the commonly used Chelex-100 resin and boiling
10 technique. We have explored extraction of total nucleic acids from saliva and salivary sputum sample
11 spiked with TB and SARS-CoV-2 and demonstrated compatibility across various tests and platforms. We
12 propose a simple protocol that eliminates the need for specialized equipment, enabling streamlined multi-
13 pathogen testing in community centers. To the best of our knowledge, no study has previously attempted
14 to co-extract total nucleic acids from *Mtb* and *SC2* using the same sample type.

15

16 **METHODS**

17

18 **Ethics statement.** All discarded and de-identified patient samples were collected under the approval from
19 the Rutgers Institutional review board protocol number Pro2020001138.

20

21 **Bacterial cultures.** An attenuated strain of *M. tuberculosis* H37Rv (mc²6230, *Mtb*), and a vaccine strain
22 *M. bovis* BCG (BCG) were used in all the experiments here unless indicated. Both were cultured in BD
23 DIFCO™ 7H9 Middlebrook broth supplemented with 10% Middlebrook OADC growth supplement (BD)
24 and 0.05% Tween 80 (Sigma Aldrich, St Louis, MO) as per the manufacturer's recommendations (BD,
25 Franklin Lakes, NJ). *M. tuberculosis* H37Rv (mc²6230, a kind gift from Dr. William Jacobs, Jr., Albert

1 Einstein College of Medicine, Bronx, NY), has independent deletions in the *panC* and *panD* genes and
2 requires media supplemented with 24 µg/ml of Calcium Pantheonate (Sigma Aldrich, St Louis, MO).
3 Both strains were then grown to an optical density OD of 0.6-0.8 and sub-cultured twice and quantitated
4 by plating on Middlebrook 7H10 agar plates (BD). The grown culture stock was mixed, aliquoted and
5 stored at -80°C until further use. For spiking experiments, an aliquot of the quantified stock culture was
6 thawed at 4°C, sonicated twice for 30s (Branson CPX1800-E Ultrasonic water bath, Danbury, CT) to
7 ensure breakage of clumps and uniform distribution of cells. Ten-fold serial dilutions were made in 7H9
8 broth and spiked at required concentrations to the matrix (either pooled or individual sputum/saliva
9 collected from non-TB suspects).

10
11 **Clinical Samples.** Saliva and sputum were used as clinical matrix for this evaluation. Samples were
12 collected from 39 participants at the University Hospital (UH) in Newark, NJ, USA between May 2022
13 and November 2023 under an approved IRB protocol (Rutgers eIRB # Pro2020001138). Participants were
14 diagnosed with non-TB conditions, including non-respiratory conditions (foot laceration, femur fracture,
15 etc) or respiratory conditions (e.g. COPD, asthma, fluid overload due to congestive heart failure) who
16 could produce expectorated sputum. Clinical characteristics, including gender, age, and underlying
17 conditions, are shown in Supplementary Table 3. Samples were characterized based on physical
18 properties, logged, aliquoted, and stored at -80°C until use. The use of the terminology salivary sputum
19 refers to 1:1 diluted saliva in sputum. All individual sputum samples were tested by IS6110-dPCR to
20 confirm that they were *Mtb*-negative before spiking with *Mtb*.

21
22 **Optimization of sample processing protocol.** Sample processing buffer was designed using Chelex-100
23 resin based Instagene Matrix (Biorad) as the base reagent. We explored supplementing Chelex-100 with
24 various detergents such as Nonidet P-40 (NP-40, Sigma), Tween20 (Sigma), Tergitol (Sigma), and
25 TritonX (Sigma) at 1% concentration, for enhanced nucleic acid recovery. Negative saliva obtained from
26 BioIVT, Westbury, NY (from 4 known, *Mtb*-negative participants), and was confirmed again at our lab

1 using Xpert MTB/RIF ultra test. All samples were pooled at equal volumes and mixed via snap vortexing.
2 Sputum collected from discarded patient samples from the microbiology lab at the University Hospital,
3 Newark, NJ were pooled separately based on physical characteristics to evaluate the variability of the
4 sputum sample type. The pools were verified negative by Xpert MTB/RIF Ultra test (Ultra, Cepheid,
5 Sunnyvale, CA).

6 The initial protocol involved adding 200µl of the Chelex based buffer to 100µl of spiked (*Mtb* at
7 ~10⁶ CFU/ml) saliva/sputum in a screw-cap Eppendorf tube with an O-ring. The samples were vortexed
8 for 30s at 3400 rpm, incubated for 30 min at 95°C, and then centrifuged for 2 min at 9400 xg. The
9 supernatant containing the nucleic acid was carefully collected (~100µl). All the extracted samples were
10 analyzed via the qPCR IS6110 assay, dPCR IS6110 assay and the CRISPR-Cas13a IS6110/IS1081 assay.

11
12 **Assays Used for Validation.** Primer and probe sequences for different assays used here are mentioned in
13 Table S2, where IS6110 assay (23), and *acr* assay (36) were used as targets for *M. tuberculosis* detection
14 and N1 assay (37) for SARS-CoV-2 .

15 The QIAcuity ProbePCR kit (Qiagen, Hilden, Germany) was used for QIAcuity Digital PCR
16 System. The reaction components varied based on the nanoplate type, but the standardized kit-
17 recommended reaction mix and cycling conditions were utilized. For 8.5K nanoplates (Qiagen, Hilden,
18 Germany), the 12µl reaction mix was comprised of 3µl of PCR Master Mix (Qiagen, Hilden, Germany),
19 0.8µM of each primer, 0.4µM of probe, 5.8µl of water; and 2µl of DNA. For 26K nanoplates (Qiagen,
20 Hilden, Germany), the 40µl reaction mix was comprised of 10µl of ProbePCR Master Mix, 0.8µM of
21 each primer, 0.4µM of probe, 5.8µl of water; and 2µl of DNA. The dPCR cycling conditions were
22 followed as per the manufacturer's instructions (Qiagen), which included an initial heat activation at 95°C
23 for 2 min, then 40 cycles of denaturation at 95°C for 15s, and annealing/extension at 60°C for 30s.

24 Real time PCR was performed in the LightCycler 480 system, in a 384 well microliter plate at a
25 reaction volume of 12 µl (using the QIAcuity probe PCR kit), comprised of 3µl of ProbePCR Master Mix
26 (Qiagen, Hilden, Germany), 0.8µM of each primer, 0.4µM of *acr/IS6110* assay probe, 5.8µl of water; and

1 2µl of DNA. The PCR cycling conditions included an initial heat activation at 95°C for 2 min, then 40
2 cycles of denaturation at 95°C for 15s, and annealing at 60°C for 30 s. and extension at 72°C, 15 s. The
3 fluorescence was recorded during the annealing step of the assay.

4 CRISPR SHINE-TB test was performed using the single-step Cas13a assay developed by our
5 team (38) and CRISPR SHINEv.2 SARS-CoV-2 test (20). Briefly, SHINE-TB test master mix contained
6 SHINE buffer (20 mM HEPES pH 8.0, 60 mM KCl, 3.5% PEG-8000, nuclease-free (nf) water), 45 nM
7 *Lwa*Cas13a (Genscript, stored in 100 mM Tris HCl pH 7.5 and 1 mM DTT), 0.3 nM of each rNTP (New
8 England Biolabs), 1 U/mL T7 RNAP (Biosearch Technologies), 62.5 nM FAM 6U quenched reporter (5'-
9 /56-FAM/rUrUrUrUrUrU/3IABkFQ/-3'; IDT), 22.5 nM of each crRNA in a combination, 70 nM of the
10 appropriate RPA primers in nf water and finally, 14 mM MgOAc. Assays were performed by mixing
11 completed Cas13a master mix (90% by volume) with target (10% by volume). Reactions were loaded in
12 technical triplicates into 384-well clear-bottom microplates (Greiner) for 15 µL reactions or 20 µL
13 reactions in 384-well microplates (Corning). The plates were incubated at 37°C for up to 3 hours in an
14 Agilent BioTek Cytation 5 microplate reader, with fluorescence readings programmed to record every 5
15 minutes.

16
17 **Extraction efficiency.** *M. bovis* BCG was spiked to pooled sputum at different concentrations at 10⁵, 10⁴,
18 10³ and 10 CFU/ml and total nucleic acids were extracted following the protocol described in Fig. 2a.
19 The dPCR was performed using IS6110 assay following the method explained earlier. Extraction
20 efficiency was calculated using the formula Extraction Efficiency (%) = (DNA quantity recovered / Initial
21 DNA quantity) x 100.

22

23

1 RESULTS

2

3 **Optimization of Chelex-100 resin based sample processing for saliva and sputum.** To evaluate the
4 effect of different detergents commonly used to improve extraction yield from bacteria, the Chelex-100
5 resin (Instagene matrix) was supplemented with various detergents (Fig. 1) and tested on individual saliva
6 and two different sputum samples (Fig. 1c) spiked with *Mtb* at 10^6 CFU/ml. DNA extracted using boil
7 preparation method described in the methods was evaluated with dPCR (Fig. 1a), and the CRISPR-based
8 SHINE-TB test (Fig. 1b). The results showed no significant difference ($P>0.05$) between Chelex-100 with
9 and without detergents for sputum pools A and B. However, for saliva, an improvement was observed
10 with the addition of NP-40, Tergitol, and Triton-X-100 (Fig. 1a). With the CRISPR SHINE-TB assay, the
11 yield of sputum B was no different compared to that of saliva in all conditions ($P>0.05$, Fig. 1b).
12 Conversely for sputum A, the test failed across all Chelex +/- resin-based solutions (Fig. 1b), which could
13 be due to the presence of inhibitors in sputum A, which was more darkly colored and mucoidal than
14 sputum B (Fig. 1c). Considering the natural biological variation expected with sputum samples, further
15 testing and optimization were necessary to efficiently detect *Mtb* from sputum in CRISPR-based tests.

16

17 **Saliva sample processing and detection in NAA-based methods.** A confirmed negative saliva sample
18 pool (BioIVT, NY) was spiked with *Mtb* H37Rv mc²6230 at logarithmic dilutions ranging from 10^6 CFU
19 to 100 CFU/ml. *Mtb* DNA was extracted from saliva using the optimized Chelex resin-based boil prep
20 (CRB) protocol as described in Fig. 2a. The extracted DNA from different mycobacterial concentrations
21 was tested across a variety of *Mtb* detection assays using different platforms, demonstrating compatibility
22 across multiple methods. Real-time PCR targeting the *Mtb acr* gene was performed using the Roche
23 LC480 system (Fig. 2b), while digital PCR (dPCR) on the Qiacuity platform (Fig. 2c) and the CRISPR-
24 based SHINE-TB test (Fig. 2d and e) targeted the *Mtb IS6110* gene. Detection sensitivity varied between
25 assays. The *acr* assay, which targets a single-copy gene, showed a sensitivity of 100% (9/9) at

1 concentrations greater than 10^4 CFU/ml but dropped below 50% at 10^3 CFU/ml (4/9) and 10^2 CFU/ml
2 (5/9) of *Mtb* spiked in saliva.

3 However, the dPCR and SHINE-TB tests, both targeting the multi-copy *IS6110* gene, exhibited a
4 100% sensitivity at 100 CFU/ml (Fig. 2). These results indicate that *Mtb* DNA extracted from saliva using
5 our optimized protocol is free of inhibitors and applicable across a broad range of platforms and *Mtb*
6 detection assays.

7
8 **Sputum sample processing optimization for CRISPR-SHINE TB test.** Sputum is a widely used and
9 accepted sample type for TB testing and as shown in Fig. 1, we observed variability in detection with
10 different sputum pools, primarily affecting SHINE-TB more than qPCR or dPCR. To assess this, we first
11 evaluated 10 individual sputum samples collected from 10 different TB-unsuspected patients using the
12 SHINE-TB test (Fig. 3a) using our CRB protocol mentioned in Fig. 2a. Remarkably, 5 out of 10 samples
13 failed to detect *M. bovis* BCG at a concentration of 10^4 CFU/ml. We suspected two possible reasons for
14 this failure: (1) insufficient mycobacterial lysis or (2) the presence of assay-specific inhibitors affecting
15 Cas or RPA activity.

16 To address the issue of insufficient lysis, we tested ready-to-use 2 ml tubes containing Lysing
17 Matrix B beads (LMB, MP Biomedicals), which are 0.1 mm silica spheres designed to enhance *Mtb* lysis
18 efficiency. *M. bovis* BCG was spiked at 10^4 CFU/ml into a pooled sputum sample composed of the five
19 previously undetected samples (Sp-02, Sp-06, Sp-07, Sp-08, and Sp-09). DNA was then extracted using a
20 modified CRB protocol (Fig. 2a), where LMB tubes replaced standard Eppendorf tubes. A 2 μ l aliquot of
21 the extracted DNA was tested using dPCR.

22 As shown in Fig. 3b and Fig. S1, the use of LMBs resulted in a 2-log $\square\square$ increase in BCG copy
23 number in spiked sputum compared to extractions without LMBs, demonstrating the positive effect of the
24 beads on bacterial lysis and DNA yield. Further dPCR testing with 21 individual sputum samples spiked
25 with BCG consistently showed higher detection rates when LMBs were used, with all samples (21/21)

1 successfully detected. However, genomic copy numbers varied from 1,208 to 18,100, indicating some
2 variability in extraction efficiency among samples.

3 When the same set of 21 samples was tested using the CRISPR SHINE-TB assay, 17 out of 21
4 samples (81%) were detected, while four samples (Sp-02, Sp-06, Sp-09, and Sp-11, Fig. 3d) remained
5 undetected. Improper lysis or extraction was unlikely to be the cause of these failures, as dPCR confirmed
6 that all undetected samples, except Sp-11, contained $\geq 10^4$ genomic copies per reaction, well above the
7 established limit of detection (LoD) for SHINE-TB (< 100 CFU/ml, (38)). Sp-11 showed a lower copy
8 number in dPCR (Fig. 3c), which may partially explain its failure to be detected.

9 Given these findings, we suspected the presence of inhibitors specific to RPA or Cas enzymes as
10 the potential reason for assay failure. To test this hypothesis, we applied a simple dilution approach using
11 TE buffer. We found that when the sample-to-TE buffer ratio exceeded 40% (i.e., 40% TE buffer and 60%
12 sputum), SHINE-TB positivity was restored (Fig. 3e), supporting our hypothesis. Further experimentation
13 is required to determine whether RPA- or Cas-specific inhibition is the primary factor. However, we were
14 unable to conduct additional tests with the specific inhibitory sputum samples due to limited sample
15 volume.

16 Nevertheless, we selected a 1:1 sputum-to-TE buffer dilution for further testing of inhibitory
17 sputum samples from Fig. 3d. This dilution approach had somewhat positive impact, where 2 of the 4
18 samples tested positive (Fig. 3f). Further optimization and purification may be necessary to improve
19 sputum testing with CRISPR-Cas-based assays.

20 Using this simple boil preparation method in combination with lysis beads and dilution (CRB,
21 Fig. 4a), we established that the eluate from saliva and salivary sputum is compatible with a variety of
22 platforms, including qPCR (LC480), dPCR (QiaCuity), and CRISPR-based SHINE-TB assays (Fig. 4).

23 Extraction efficiency, calculated from the data using *M. bovis* BCG spiked into sputum at
24 different concentrations, was found to be 48% at 10^4 CFU/ml, 62.2% at 10^5 CFU/ml, 86.4% at 10^6
25 CFU/ml, and 99.3% at 10^7 CFU/ml, with an overall average extraction efficiency of approximately 74%.

26

1 **Co-extraction of *Mtb* and SARS-CoV-2 spiked in a single salivary sputum.** *M. bovis* BCG and
2 inactivated SARS-CoV-2 USA WA1/2020 (SC2) strains were spiked at 10^5 CFU/ml or 10^5 PFU/ml to
3 pooled negative salivary sputum samples at different conditions. A set of samples (N=3) contained only
4 *M. bovis* BCG and a second set contained only SC2 and a third set contained both organisms spiked at 1:1
5 ratio. The samples were processed using the optimized sputum processing protocol as described in Fig.
6 4a.

7 All samples were evaluated using both dPCR and CRISPR SHINE-TB. As shown in Fig. 5, both BCG
8 DNA (Fig. 5a, c) and SC2 RNA (Fig. 5b, d), were efficiently extracted using our CRB protocol and
9 detected using both dPCR and SHINE-TB.

10

11 **DISCUSSION**

12

13 In this study, we have optimized and developed a simple, rapid and efficient sample processing method
14 for total nucleic acid extraction from saliva and salivary sputum as a potential sample type for dual
15 respiratory pathogen detection. This method utilizes Chelex-100 resin (Instagene Matrix) and a lysing
16 matrix tube with 0.1 mm silica beads, combined with heating at 95°C, which demonstrated an extraction
17 efficiency ranging from 48% (for 10^5 CFU/ml) to as high as 99.3% (10 CFU/ml), which is better than the
18 published methods (39, 40).

19 Considering *M. tuberculosis* (*Mtb*) is a hardy and difficult-to-lyse bacterium compared to SC2,
20 our initial studies focused on optimizing *Mtb* lysis in both saliva and sputum. While sputum has been the
21 primary specimen of choice for TB diagnosis, it presents various challenges for nucleic acid amplification
22 tests. Alternative sample types such as saliva (18), oral swabs (41) and tongue swabs (42) have shown
23 promise for respiratory pathogen detection. Saliva has been widely used for SARS-CoV-2 (SC2)
24 diagnosis, which has shown significant variability in physical characteristics and potential contaminants
25 (e.g., blood, drugs, food, tissue), necessitating careful optimization to maximize pathogen nucleic acid
26 extraction efficiency. The choice of extraction protocol depends on the intended downstream

1 application—while crude extracts suffice for most PCR-based diagnostics, higher-quality samples are
2 required for whole-genome sequencing or transcriptomics.

3 For point-of-care (POC) diagnostic testing, we screened simple and low-cost methods that can be
4 used by non-laboratory personnel. After a thorough literature search, we identified procedures and their
5 limitations that overlap between standard viral and bacterial extraction methods and require minimal
6 manipulation (Supplementary Table 1); ideally steps that are utilized in the field currently. Chelex-100
7 resin and heating seem to be commonly utilized for both *SC2* and *Mtb*, so these procedures were
8 evaluated for our purposes. CRISPR-based diagnostic testing is emerging as a highly promising POC
9 method for pathogen surveillance and strain identification (20, 43-45). However, comprehensive
10 evaluation and optimization of sputum sample processing remain critical for TB detection.

11 We demonstrated that nucleic acids extracted using our method from *Mtb*-spiked saliva and
12 sputum were compatible across different platforms, including LC480 qPCR, Qiacuity digital PCR
13 (dPCR), and the CRISPR-based SHINE-TB test, detecting as low as 100 CFU/ml (Fig. 2, (38)). However,
14 *Mtb*-spiked individual sputum samples showed lower compatibility, with an 82% positivity rate (18/22,
15 Fig. 3d) compared to 100% detection using dPCR (Fig. 3c). The decreased detection rate in some samples
16 (Sp-06, Sp-07, Sp-09, Sp-11) may be due to the presence of assay-specific inhibitors affecting the
17 CRISPR test, such as recombinase polymerase amplification (RPA) or Cas enzymes, which require
18 further investigation. Our preliminary tests with extracted negative matrices spiked with DNA did not
19 show inhibition, and even the presence of up to 10% blood in saliva did not affect SHINE-TB
20 performance (Fig. S2), suggesting effective removal of common inhibitors by our CRB protocol. To
21 mitigate potential Cas/RPA enzyme inhibition, dilution with TE buffer (1:1) rescued 50% (2/4) of the
22 inhibitory samples. Additionally, we explored mass-based filter tips (Monolith, C18 resin, C4 resin, strong
23 cationic resin) to isolate genomic material from large macromolecules (e.g., lipids, proteins, food) (Fig.
24 S3 A); PCR additives (Fig. S3 B); and varying concentrations of Chelex-100 resin (6%–20%, Fig. S3 C),
25 but with limited success. Due to sample volume constraints, we could not repeat testing on all failed
26 samples. These findings suggest that further sample cleanup may be necessary for some sputum samples

1 to improve with CRISPR-based diagnostic tests. Further investigation is required to identify the inhibitors
2 and develop targeted measures to mitigate their effects.

3 We also demonstrated our protocol's ability to co-extract total nucleic acids (DNA and RNA)
4 from *Mtb* and *SC2*, enabling dual detection using SHINE-TB (38) and SHINE-CoV-2 (37) assays (Fig. 5),
5 as well as dPCR targeting the *NI* gene for *SC2* and *IS6110* for TB (Fig. 5). To our knowledge, this is the
6 first reported co-extraction protocol from a single sample for simultaneous detection of both pathogens.
7 Further work is underway to simplify the process, reduce processing time, improve sensitivity, and ensure
8 nucleic acid stability. Additionally, we are currently investigating *Mtb* inactivation using the MGIT
9 system.

10 In summary, we have successfully optimized a simple, rapid and efficient DNA/RNA co-
11 extraction method for multi-pathogen testing, demonstrating compatibility across various diagnostic
12 platforms. This co-extraction protocol for two very different pathogens may be adapted to other
13 organisms to synergize TB and future pandemic surveillance and enhance routine multipathogen
14 respiratory diagnostics. Ongoing optimization efforts will focus on expanding compatibility to additional
15 respiratory specimens. The WHO is advocating for rapid and sensitive diagnostic approaches for
16 pulmonary and extrapulmonary TB using non-sputum samples to enable same-day treatment initiation in
17 resource-limited health clinics (46, 47). Future directions include eliminating or minimizing the need for
18 specialized equipment, reducing time of incubation, enabling diagnostic testing directly in household
19 settings for rapid medical diagnosis, and evaluating alternative sample types such as oral and tongue
20 swabs.

21
22
23
24
25
26

1
2
3
4
5
6
7
8
9
10

ACKNOWLEDGEMENTS.

Funding was provided by the National Institutes of Health (NIH) R21 AI168808 (Y.L.X., P.B., C.M.), NIH R01 AI182281 (Y.L.X, C.M.), New Jersey Alliance for Clinical and Translational Science (NJACTS) UL1TR003017 (Y.L.X., P.B., C.M.) and Centers for Disease Control and Prevention 75D30122C15113 (C.M.). A.G.B. was supported by NIH Training Grants T32GM148739 and T32GM007388. We wish to thank Dr. David Alland for guidance and support.

1 **AUTHOR CONTRIBUTIONS.**

2 P.B., Y.L.X., C.M. conceptualized, supervised the study, and approved the final manuscript. N.M.
3 performed the experiments and wrote the initial manuscript draft. P.B. finalized the manuscript with input
4 from all authors. A.B, O.D., N.D., Y.H. performed supporting experiments and assisted with study
5 implementation, A.W. and E.H. enrolled saliva and sputum donors.

6

1 REFERENCES.

- 2 1. Trajman A, Felker I, Alves LC, Coutinho I, Osman M, Meehan SA, Singh UB, Schwartz Y. 2022.
3 The COVID-19 and TB syndemic: the way forward. *Int J Tuberc Lung Dis* 26:710-719.
- 4 2. WHO. 2024. Number of COVID-19 cases reported to WHO, Geneva.
- 5 3. WHO. 2024. Global tuberculosis report 2024. World Health Organization, Geneva.
- 6 4. Bagcchi S. 2023. WHO's Global Tuberculosis Report 2022. *Lancet Microbe* 4:e20.
- 7 5. Pokam BDT, Shindoh EN, Djuikoue CI, Nana CS, Kakah SH, Elisee APK, Tendongfor N. 2024.
8 The Effects of Coronavirus Disease-19 Pandemic on Tuberculosis Treatment Uptake and
9 Outcomes in the Fako Division of Cameroon. *Int J Mycobacteriol* 13:387-393.
- 10 6. WHO. 2024. Epidemiological Update: SARS-CoV-2 and Other Respiratory Viruses in the
11 Americas Region PAHO/WHO, Washington, D.C.
- 12 7. WHO. 2024. Tuberculosis resurges as top infectious disease killer.
- 13 8. Jeong Y, Min J. 2023. Impact of COVID-19 Pandemic on Tuberculosis Preventive Services and
14 Their Post-Pandemic Recovery Strategies: A Rapid Review of Literature. *J Korean Med Sci*
15 38:e43.
- 16 9. Dheda K, Perumal T, Moultrie H, Perumal R, Esmail A, Scott AJ, Udhwadia Z, Chang KC, Peter J,
17 Pooran A, von Delft A, von Delft D, Martinson N, Loveday M, Charalambous S, Kachingwe E,
18 Jassat W, Cohen C, Tempia S, Fennelly K, Pai M. 2022. The intersecting pandemics of
19 tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and
20 corrective interventions. *Lancet Respir Med* 10:603-622.
- 21 10. Falzon D, Zignol M, Bastard M, Floyd K, Kasaeva T. 2023. The impact of the COVID-19
22 pandemic on the global tuberculosis epidemic. *Front Immunol* 14:1234785.
- 23 11. Ranasinghe L, Achar J, Gröschel MI, Whittaker E, Dodd PJ, Seddon JA. 2022. Global impact of
24 COVID-19 on childhood tuberculosis: an analysis of notification data. *Lancet Glob Health*
25 10:e1774-e1781.
- 26 12. Genade LP, Kahamba T, Scott L, Tempia S, Walaza S, David A, Stevens W, Hlongwane K, von
27 Gottberg A, Du Plessis M, Kleynhans J, Cohen C, Martinson NA. 2023. Co-testing a single
28 sputum specimen for TB and SARS-CoV-2. *Int J Tuberc Lung Dis* 27:146-147.
- 29 13. Scott AJ, Limbada M, Perumal T, Jaumdally S, Kotze A, van der Merwe C, Cheeba M, Milimo D,
30 Murphy K, van Ginneken B, de Kock M, Warren RM, Gina P, Swanepoel J, Kühn L, Oelofse S,
31 Pooran A, Esmail A, Ayles H, Dheda K. 2024. Integrating molecular and radiological screening
32 tools during community-based active case-finding for tuberculosis and COVID-19 in southern
33 Africa. *International Journal of Infectious Diseases* 145:107081.
- 34 14. MacLean E, Kohli M, Weber SF, Suresh A, Schumacher SG, Denkinge CM, Pai M. 2020.
35 *Advances in Molecular Diagnosis of Tuberculosis*. *J Clin Microbiol* 58.
- 36 15. Akowuah E, Acheampong G, Ayisi-Boateng NK, Amaniampong A, Agyapong FO, Senyo
37 Kamasah J, Agyei G, Owusu DO, Nkrumah B, Mutocheluh M, Sylverken AA, Owusu M. 2022.
38 Comparable Detection of SARS-CoV-2 in Sputum and Oropharyngeal Swab Samples of
39 Suspected COVID-19 Patients. *COVID* 2:858-866.
- 40 16. Banada P, Elson D, Daivaa N, Park C, Desind S, Montalvan I, Kwiatkowski R, Chakravorty S,
41 Alland D, Xie YL. 2021. Sample collection and transport strategies to enhance yield,
42 accessibility, and biosafety of COVID-19 RT-PCR testing. *J Med Microbiol* 70.
- 43 17. Marín-Echeverri C, Pérez-Zapata L, Álvarez-Acevedo L, Gutiérrez-Hincapié S, Adams-Parra M,
44 Tirado-Duarte D, Bolívar-Muñoz J, Gallego-Gómez M, Galeano-Castañeda Y, Piedrahita-Ochoa
45 C, Del Valle Arrieta H. 2024. Diagnostic performance, stability, and acceptability of self-collected
46 saliva without additives for SARS-CoV-2 molecular diagnosis. *Eur J Clin Microbiol Infect Dis*
47 43:1127-1138.
- 48 18. Ayalew S, Wegayehu T, Wondale B, Kebede D, Osman M, Niway S, Tarekegn A, Tessema B,
49 Berg S, Ashford RT, Mihret A. 2024. Detection of *Mycobacterium tuberculosis* complex in saliva

- 1 by quantitative PCR: A potential alternative specimen for pulmonary tuberculosis diagnosis.
2 Tuberculosis 148:102554.
- 3 19. Namuganga AR, Chegou NN, Mubiri P, Walzl G, Mayanja-Kizza H. 2017. Suitability of saliva
4 for Tuberculosis diagnosis: comparing with serum. BMC Infect Dis 17:600.
- 5 20. Arizti-Sanz J, Bradley AD, Zhang YB, Boehm CK, Freije CA, Grunberg ME, Kosoko-
6 Thoroddsen T-SF, Welch NL, Pillai PP, Mantena S, Kim G, Uwanibe JN, John OG, Eromon PE,
7 Kocher G, Gross R, Lee JS, Hensley LE, MacInnis BL, Johnson J, Springer M, Happi CT, Sabeti
8 PC, Myhrvold C. 2022. Simplified Cas13-based assays for the fast identification of SARS-CoV-2
9 and its variants. Nature Biomedical Engineering 6:932-943.
- 10 21. Datta M, Singh DD, Naqvi AR. 2021. Molecular Diagnostic Tools for the Detection of SARS-
11 CoV-2. Int Rev Immunol 40:143-156.
- 12 22. Kostyusheva A, Brezgin S, Babin Y, Vasilyeva I, Glebe D, Kostyushev D, Chulanov V. 2022.
13 CRISPR-Cas systems for diagnosing infectious diseases. Methods 203:431-446.
- 14 23. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S,
15 Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C,
16 Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R,
17 Jones M, Alland D. 2017. The New Xpert MTB/RIF Ultra: Improving Detection of
18 *Mycobacterium tuberculosis* and Resistance to Rifampin in an Assay Suitable for Point-of-Care
19 Testing. mBio 8.
- 20 24. Andrianto A, Mertaniasih NM, Gandi P, Al-Farabi MJ, Azmi Y, Jonatan M, Silahooij SI. 2020.
21 Diagnostic test accuracy of Xpert MTB/RIF for tuberculous pericarditis: a systematic review and
22 meta-analysis. F1000Res 9:761.
- 23 25. Promsena P, Jantarabenjakul W, Suntarattiwong P, Sudjaritruk T, Anugulruengkitt S,
24 Rotcheewaphan S, Petsong S, Sawangsinth P, Sophonphan J, Tawan M, Moonwong J, Puthanakit
25 T. 2022. Diagnostic Accuracy of Loop-Mediated Isothermal Amplification (TB-LAMP) for
26 Tuberculosis in Children. J Pediatric Infect Dis Soc 11:9-15.
- 27 26. Sam IK, Chen YY, Ma J, Li SY, Ying RY, Li LX, Ji P, Wang SJ, Xu J, Bao YJ, Zhao GP, Zheng
28 HJ, Wang J, Sha W, Wang Y. 2021. TB-QUICK: CRISPR-Cas12b-assisted rapid and sensitive
29 detection of *Mycobacterium tuberculosis*. J Infect 83:54-60.
- 30 27. Yan L, Xiao H, Zhang Q. 2016. Systematic review: Comparison of Xpert MTB/RIF, LAMP and
31 SAT methods for the diagnosis of pulmonary tuberculosis. Tuberculosis (Edinb) 96:75-86.
- 32 28. Loeffelholz MJ, Alland D, Butler-Wu SM, Pandey U, Perno CF, Nava A, Carroll KC, Mostafa H,
33 Davies E, McEwan A, Rakeman JL, Fowler RC, Pawlotsky JM, Fourati S, Banik S, Banada PP,
34 Swaminathan S, Chakravorty S, Kwiatkowski RW, Chu VC, Kop J, Gaur R, Sin MLY, Nguyen D,
35 Singh S, Zhang N, Persing DH. 2020. Multicenter Evaluation of the Cepheid Xpert Xpress
36 SARS-CoV-2 Test. J Clin Microbiol 58.
- 37 29. Banada PP, Green R, Streck D, Kurvathi R, Reiss R, Banik S, Daivaa N, Montalvan I, Jones R,
38 Marras SAE, Chakravorty S, Alland D. 2023. An expanded RT-PCR melting temperature coding
39 assay to rapidly identify all known SARS-CoV-2 variants and sub-variants of concern. Sci Rep
40 13:21927.
- 41 30. Banada P, Green R, Banik S, Chopoorian A, Streck D, Jones R, Chakravorty S, Alland D. 2021. A
42 Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-
43 CoV-2 Variants. medRxiv doi:10.1101/2021.03.05.21252709.
- 44 31. Broger T, Marx FM, Theron G, Marais BJ, Nicol MP, Kerkhoff AD, Nathavitharana R, Huerga H,
45 Gupta-Wright A, Kohli M, Nichols BE, Muyoyeta M, Meintjes G, Ruhwald M, Peeling RW, Pai
46 NP, Pollock NR, Pai M, Cattamanchi A, Dowdy DW, Dewan P, Denkinger CM. 2024. Diagnostic
47 yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance
48 for future research. Lancet Glob Health 12:e1184-e1191.
- 49 32. Aldous WK, Pounder JI, Cloud JL, Woods GL. 2005. Comparison of six methods of extracting
50 *Mycobacterium tuberculosis* DNA from processed sputum for testing by quantitative real-time
51 PCR. J Clin Microbiol 43:2471-3.

- 1 33. Chakravorty S, Tyagi JS. 2001. Novel use of guanidinium isothiocyanate in the isolation of
2 *Mycobacterium tuberculosis* DNA from clinical material. FEMS Microbiol Lett 205:113-7.
- 3 34. Koentjoro MP, Donastin A, Prasetyo EN. 2021. A simple method of dna extraction of
4 *Mycobacterium tuberculosis* from sputum cultures for sequencing analysis. Afr J Infect Dis
5 15:19-22.
- 6 35. Thakore N, Norville R, Franke M, Calderon R, Lecca L, Villanueva M, Murray MB, Cooney CG,
7 Chandler DP, Holmberg RC. 2018. Automated TruTip nucleic acid extraction and purification
8 from raw sputum. PLoS One 13:e0199869.
- 9 36. Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, Van T, Chen RY,
10 Warwick J, Via LE, Song T, Lee M, Schoolnik G, Tromp G, Alland D, Barry CE, 3rd, Winter J,
11 Walzl G, Lucas L, Spuy GV, Stanley K, Thiart L, Smith B, Du Plessis N, Beltran CG, Maasdorp
12 E, Ellmann A, Choi H, Joh J, Dodd LE, Allwood B, Koegelenberg C, Vorster M, Griffith-
13 Richards S. 2016. Persisting positron emission tomography lesion activity and *Mycobacterium*
14 *tuberculosis* mRNA after tuberculosis cure. Nat Med 22:1094-1100.
- 15 37. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, Lynch B, Malapati L, Burke SA,
16 Harcourt J, Tamin A, Thornburg NJ, Villanueva JM, Lindstrom S. 2020. US CDC Real-Time
17 Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome
18 Coronavirus 2. Emerg Infect Dis 26:1654-65.
- 19 38. Dunkley ORS, Bell AG, Modi NH, Huang Y, Tseng S, Reiss R, Daivaa N, Davis JL, Vargas DA,
20 Banada P, Xie YL, Myhrvold C. 2025. A Streamlined Point-of-Care CRISPR Test for
21 Tuberculosis Detection Directly from Sputum. medRxiv
22 doi:10.1101/2025.02.19.25322517:2025.02.19.25322517.
- 23 39. Kolia-Diafouka P, Godreuil S, Bourdin A, Carrère-Kremer S, Kremer L, Van de Perre P, Tuailon
24 E. 2018. Optimized Lysis-Extraction Method Combined With IS6110-Amplification for Detection
25 of *Mycobacterium tuberculosis* in Paucibacillary Sputum Specimens. Frontiers in Microbiology
26 9.
- 27 40. Pan S, Gu B, Wang H, Yan Z, Wang P, Pei H, Xie W, Chen D, Liu G. 2013. Comparison of four
28 DNA extraction methods for detecting *Mycobacterium tuberculosis* by real-time PCR and its
29 clinical application in pulmonary tuberculosis. Journal of Thoracic Disease 5:251-257.
- 30 41. Church EC, Steingart KR, Cangelosi GA, Ruhwald M, Kohli M, Shapiro AE. 2024. Oral swabs
31 with a rapid molecular diagnostic test for pulmonary tuberculosis in adults and children: a
32 systematic review. Lancet Glob Health 12:e45-e54.
- 33 42. Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L, Bukirwa
34 A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna I, Nyawere J,
35 Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC, Weigl BH, Connelly
36 J, Worodria W, Cattamanchi A. 2024. New Manual Quantitative Polymerase Chain Reaction
37 Assay Validated on Tongue Swabs Collected and Processed in Uganda Shows Sensitivity That
38 Rivals Sputum-based Molecular Tuberculosis Diagnostics. Clinical Infectious Diseases 78:1313-
39 1320.
- 40 43. Arizti-Sanz J, Freije CA, Stanton AC, Petros BA, Boehm CK, Siddiqui S, Shaw BM, Adams G,
41 Kosoko-Thoroddsen T-SF, Kembell ME, Uwanibe JN, Ajogbasile FV, Eromon PE, Gross R,
42 Wronka L, Caviness K, Hensley LE, Bergman NH, MacInnis BL, Happi CT, Lemieux JE, Sabeti
43 PC, Myhrvold C. 2020. Streamlined inactivation, amplification, and Cas13-based detection of
44 SARS-CoV-2. Nature Communications 11:5921.
- 45 44. de Puig H, Lee RA, Najjar D, Tan X, Soenksen LR, Angenent-Mari NM, Donghia NM, Weckman
46 NE, Ory A, Ng CF, Nguyen PQ, Mao AS, Ferrante TC, Lansberry G, Sallum H, Niemi J, Collins
47 JJ. 2021. Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-
48 care diagnosis of SARS-CoV-2 and emerging variants. Science Advances 7:eabh2944.
- 49 45. Joung J, Ladha A, Saito M, Kim N-G, Woolley AE, Segel M, Barretto RPJ, Ranu A, Macrae RK,
50 Faure G, Ioannidi EI, Krajewski RN, Bruneau R, Huang M-LW, Yu XG, Li JZ, Walker BD, Hung
51 DT, Greninger AL, Jerome KR, Gootenberg JS, Abudayyeh OO, Zhang F. 2020. Detection of

1 SARS-CoV-2 with SHERLOCK One-Pot Testing. *New England Journal of Medicine* 383:1492-
2 1494.

3 46. Kasule GW, Hermans S, Semugenze D, Wekiya E, Nsubuga J, Mwachan P, Kabugo J, Joloba M,
4 García-Basteiro AL, Ssenooba W, Elisa L-V, Belén S-C, Lucía C-C, Sergi S, Ehrlich J,
5 Fernandez C, Makhosazana D, Gcinile D, Nomathemba D, Nkulungwane M, Nokwanda K,
6 Mbongeni D, Busizwe S, Ziyane M, Mulengwa D, Adu-Gyamfi CG, Maphalala N, Babongile N,
7 Shiba N, Dlamini F, Shabalala F, Dlamini S, Maphalala G, Dlamini L, Dube S, Acacio S,
8 Munguambe S, Fonseca LJ, Cumbe M, Mambuque ET, Lima A, Magul K, Tembe G, Mudumane
9 BV, Cebola F, Rungo J, Junior AB, Gomis N, Nassolo M, Wobudeya E, et al. 2024. Non-sputum-
10 based samples and biomarkers for detection of *Mycobacterium tuberculosis*: the hope to improve
11 childhood and HIV-associated tuberculosis diagnosis. *European Journal of Medical Research*
12 29:502.

13 47. WHO. 2024. Target product profiles for tuberculosis diagnosis and detection of drug resistance.
14 World Health Organization,

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Figure legends.

Fig 1. Optimization of Chelex-100 resin based sample processing. Chelex-100 was supplemented with various detergents, and total DNA was extracted by boil prep and the eluant was tested with a) digital PCR and b) SHINE-TB cas13a assay (fluorescence at 90 min (FAM, λ Ex. 490 nm/ λ Em. 517nm)); c) Difference in the physical appearance of the two sputum samples sputum A and sputum B is shown.

Sp. Sputum; PC-Positive control ATCC Mtb H37Ra at 10^3 copies/reaction; NTC- No template control. Sputum samples A and B after pooling is shown. All conditions were compared against Chelex-100 control and P values to denote statistical significance is shown only for those samples with $P < 0.05$, all other conditions have $P > 0.05$.




Fig 2. Saliva sample processing and eluant compatibility across various platforms. a) Optimized Chelex-100 resin based boil preparation (CRB) sample processing protocol for saliva; dynamic range for total DNA extracted using the protocol with saliva tested in b) Realtime PCR (*acr* gene) in Roche LC480 (N=9), c) Qiacuity dPCR (IS6110); d) and e) SHINE-TB cas13a assay (IS6110) in Cytation 3 platform showing d) real time curves e) end point fluorescence at 90 min (FAM λ Ex. 490 nm/ λ Em. 517nm); Sp. Sputum; PC-Positive control ATCC *Mtb* H37Ra (used at 10^2 copies/reaction in dPCR); NC- non spiked saliva extraction negative control; NTC- No template reaction control; a.u- arbitrary units.






1 **Fig 3. Sputum sample processing and reduction of sample inhibition in SHINE-TB assay.** a) CRB
2 sample processing method was used to extract total DNA with various negative patient sputum samples
3 spiked with *M. bovis* BCG (10^5 CFU/ml) and was tested with SHINE-TB assay; b) optimization of CRB
4 method in dPCR supplementing with lysing matrix beads (LMB); c) evaluation of BCG spiked (10^5
5 CFU/ml) individual patient sputum samples with optimized CRB+LMB method; d) Re-evaluation of
6 SHINE-TB assay with BCG spiked (10^5 CFU/ml) individual patient sputum samples with optimized
7 CRB+LMB method. e) effect of dilution on sputum samples using Tris-EDTA buffer evaluated with
8 SHINE-TB assay; f) evaluation of inhibitory samples using TE dilution method. a), d), e) and f) SHINE-
9 TB test end point fluorescence units at 90 min (FAM λ Ex. 490 nm/ λ Em. 517nm). Sp. Sputum; PC- BCG
10 (10^5 CFU/mL) spiked saliva extraction control; NTC- No template reaction control; a.u- arbitrary units.







11
12 **Fig 4. Sputum sample processing protocol evaluation with a single copy target *M. bovis* BCG**
13 **IS6110.** a) Final optimized sputum sample processing protocol; dynamic range for total DNA extracted
14 from spiked pooled sputum was tested in b) real time PCR targeting IS6110 gene in Roche LC480 (N=8
15 with 3 biological replicates) c) Qiacuity dPCR targeting IS6110 (N=6 with 3 biological replicates and 2
16 technical replicates); c) and d) SHINE-TB cas13a assay in Cytation3 platform tested showing c) real time
17 curves (FAM λ Ex. 490 nm/ λ Em. 517nm). d) end point relative fluorescence units at 90 min (FAM λ Ex.
18 490 nm/ λ Em. 517nm).
19 PC-Positive control *M. bovis* BCG (at 2000 copies/reaction); NC- Extraction negative control; NTC- No
20 template reaction control.






21
22 **Fig 5. Co-detection of *Mtb* (10^5 CFU/ml) and SARS-CoV-2 (10^5 PFU/ml) in salivary sputum (1:1**
23 **saliva to sputum) using CRISPR Cas13 assays for *Mtb* (a) and *SC2* (b) and dPCR for *Mtb* (c) and**
24 ***SC2* (d).**

- 1 PC-Positive control *M. bovis* BCG (at 2000 copies/reaction) or SARS-CoV-2 (SC2) WT strain WA1; NC-
- 2 Extraction negative control; NTC-No template control.
- 3
- 4







a

—●— SC2 —●— SC2+BCG —●— BCG —●— PC —●— EC —●— NTC

